BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16405226)

  • 1. Making the most of managed care dollars spent for postmenopausal osteoporosis.
    Ettinger B
    Manag Care Interface; 2005 Dec; 18(12):55-9. PubMed ID: 16405226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality initiatives and health care reform.
    Renick O; Thompson RE
    Med Interface; 1996 Oct; 9(10):105-8. PubMed ID: 10161508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Low-tech" personal emergency response systems reduce costs and improve outcomes.
    Bernstein M
    Manag Care Q; 2000; 8(1):38-43. PubMed ID: 11009732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study.
    Weiss TW; Gold DT; Silverman SL; McHorney CA
    Curr Med Res Opin; 2006 May; 22(5):949-60. PubMed ID: 16709316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicaid managed care and the distribution of societal costs for persons with severe mental illness.
    Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA
    Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and cost of a systematic care program for bipolar disorder.
    Simon GE; Ludman EJ; Bauer MS; Unützer J; Operskalski B
    Arch Gen Psychiatry; 2006 May; 63(5):500-8. PubMed ID: 16651507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial.
    Majumdar SR; Beaupre LA; Harley CH; Hanley DA; Lier DA; Juby AG; Maksymowych WP; Cinats JG; Bell NR; Morrish DW
    Arch Intern Med; 2007 Oct; 167(19):2110-5. PubMed ID: 17954806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intervention thresholds for the treatment of osteoporosis: comparison of different approaches to decision-making.
    Epstein RS; Feng W; Hirsch LJ; Kelly M
    Osteoporos Int; 1998; 8 Suppl 1():S22-7. PubMed ID: 9682793
    [No Abstract]   [Full Text] [Related]  

  • 17. Short-term persistence of high health care costs in a nationally representative sample of children.
    Liptak GS; Shone LP; Auinger P; Dick AW; Ryan SA; Szilagyi PG
    Pediatrics; 2006 Oct; 118(4):e1001-9. PubMed ID: 17015496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promote customer perceptions of value: the ladder of effects.
    MacStravic S
    Manag Care Q; 1998; 6(4):1-6. PubMed ID: 10185772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the quality of care and reducing health care costs through a point-of-service health care information system.
    Zalta E
    Manag Care Q; 1995; 3(4):84-90. PubMed ID: 10151600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with osteoporosis treatment guidelines in postmenopausal women.
    Mountjoy CR; Shrader SP; Ragucci KR
    Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.